Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 66 articles:
HTML format

Single Articles

    May 2021
  1. SARNAIK AA, Hamid O, Khushalani NI, Lewis KD, et al
    Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
    J Clin Oncol. 2021 May 12:JCO2100612. doi: 10.1200/JCO.21.00612.
    PubMed     Abstract available

  2. OLSON DJ, Eroglu Z, Brockstein B, Poklepovic AS, et al
    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
    J Clin Oncol. 2021 May 4:JCO2100079. doi: 10.1200/JCO.21.00079.
    PubMed     Abstract available

    February 2021
  3. EL SHAROUNI MA, Ahmed T, Varey AHR, Elias SG, et al
    Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
    J Clin Oncol. 2021 Feb 18:JCO2002446. doi: 10.1200/JCO.20.02446.
    PubMed     Abstract available

    January 2021
    Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003523. doi: 10.1200/JCO.20.03523.

    Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003213. doi: 10.1200/JCO.20.03213.

  6. YAN X, Sheng X, Chi Z, Si L, et al
    Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 14:JCO2000902. doi: 10.1200/JCO.20.00902.
    PubMed     Abstract available

  7. PIULATS JM, Espinosa E, de la Cruz Merino L, Varela M, et al
    Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550.
    PubMed     Abstract available

  8. KHAN S, Carvajal RD
    Dual Immunological Checkpoint Blockade for Uveal Melanoma.
    J Clin Oncol. 2021 Jan 8:JCO2003274. doi: 10.1200/JCO.20.03274.

    October 2020
  9. PELSTER MS, Gruschkus SK, Bassett R, Gombos DS, et al
    Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605.
    PubMed     Abstract available

    September 2020
  10. ROBERT C, Long GV, Brady B, Dutriaux C, et al
    Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
    J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
    PubMed     Abstract available

  11. EGGERMONT AMM, Blank CU, Mandala M, Long GV, et al
    Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    J Clin Oncol. 2020 Sep 18:JCO2002110. doi: 10.1200/JCO.20.02110.
    PubMed     Abstract available

    July 2020
  12. KARAKOUSIS G, Sondak VK, Zager JS
    Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas.
    J Clin Oncol. 2020 Jul 23:JCO2001686. doi: 10.1200/JCO.20.01686.

  13. OLOFSSON BAGGE R, Kicinski M, Faries MB, Gyorki DE, et al
    Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
    J Clin Oncol. 2020 Jul 23:JCO2001680. doi: 10.1200/JCO.20.01680.

  14. HINDIE E
    Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim.
    J Clin Oncol. 2020 Jul 23:JCO2001199. doi: 10.1200/JCO.20.01199.

    June 2020
  15. LO SN, Ma J, Scolyer RA, Haydu LE, et al
    Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.
    J Clin Oncol. 2020 Jun 12:JCO1902362. doi: 10.1200/JCO.19.02362.
    PubMed     Abstract available

  16. GARBE C, Keim U, Suciu S, Amaral T, et al
    Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
    J Clin Oncol. 2020 Jun 12:JCO1903034. doi: 10.1200/JCO.19.03034.
    PubMed     Abstract available

    May 2020
    Improved Tool for Predicting Sentinel Lymph Node Metastases in Melanoma.
    J Clin Oncol. 2020 May 28:JCO2001121. doi: 10.1200/JCO.20.01121.

    April 2020
  18. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available

    March 2020
  19. SETH R, Messersmith H, Kaur V, Kirkwood JM, et al
    Systemic Therapy for Melanoma: ASCO Guideline.
    J Clin Oncol. 2020 Mar 31:JCO2000198. doi: 10.1200/JCO.20.00198.
    PubMed     Abstract available

  20. MAURICHI A, Miceli R, Eriksson H, Newton-Bishop J, et al
    Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.
    J Clin Oncol. 2020 Mar 13:JCO1901902. doi: 10.1200/JCO.19.01902.
    PubMed     Abstract available

    February 2020
    Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
    J Clin Oncol. 2020 Feb 25:JCO2000136. doi: 10.1200/JCO.20.00136.

  22. BETOF WARNER A, Palmer JS, Shoushtari AN, Goldman DA, et al
    Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
    J Clin Oncol. 2020 Feb 13:JCO1901464. doi: 10.1200/JCO.19.01464.
    PubMed     Abstract available

    January 2020
  23. HAYDU LE, Lo SN, McQuade JL, Amaria RN, et al
    Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.
    J Clin Oncol. 2020 Jan 28:JCO1901508. doi: 10.1200/JCO.19.01508.
    PubMed     Abstract available

    December 2019
  24. BETOF WARNER A, Postow MA
    Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon.
    J Clin Oncol. 2019 Dec 27:JCO1902988. doi: 10.1200/JCO.19.02988.

  25. TARHINI AA, Lee SJ, Hodi FS, Rao UNM, et al
    Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
    J Clin Oncol. 2019 Dec 27:JCO1901381. doi: 10.1200/JCO.19.01381.
    PubMed     Abstract available

    October 2019
  26. MENZER C, Menzies AM, Carlino MS, Reijers I, et al
    Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
    J Clin Oncol. 2019 Oct 3:JCO1900489. doi: 10.1200/JCO.19.00489.
    PubMed     Abstract available

    September 2019
  27. LEITER U, Stadler R, Mauch C, Hohenberger W, et al
    Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
    J Clin Oncol. 2019 Sep 26:JCO1802306. doi: 10.1200/JCO.18.02306.
    PubMed     Abstract available

  28. HONG AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, et al
    Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2019 Sep 25:JCO1901414. doi: 10.1200/JCO.19.01414.
    PubMed     Abstract available

  29. REGAN MM, Werner L, Rao S, Gupte-Singh K, et al
    Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
    J Clin Oncol. 2019 Sep 9:JCO1900345. doi: 10.1200/JCO.19.00345.
    PubMed     Abstract available

    August 2019
  30. SHENG X, Yan X, Chi Z, Si L, et al
    Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.
    J Clin Oncol. 2019 Aug 12:JCO1900210. doi: 10.1200/JCO.19.00210.
    PubMed     Abstract available

    May 2019
  31. LONG GV, Dummer R, Schadendorf D, Santinami M, et al
    Reply to E. Hindie and K.R. Hess.
    J Clin Oncol. 2019;37:1356-1358.

    April 2019
  32. KLUGER HM, Margolin KA, Davies MA, Long GV, et al
    Reply to A. Shinde et al.
    J Clin Oncol. 2019;37:1031-1032.

  33. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available

  34. HESS KR
    Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAF(V600)-Mutant Stage III Melanoma Seems to be Short-Lived.
    J Clin Oncol. 2019 Apr 2:JCO1801768. doi: 10.1200/JCO.18.01768.

  35. HINDIE E
    What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?
    J Clin Oncol. 2019 Apr 2:JCO1802075. doi: 10.1200/JCO.18.02075.

    February 2019
  36. LEBBE C, Meyer N, Mortier L, Marquez-Rodas I, et al
    Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    J Clin Oncol. 2019 Feb 27:JCO1801998. doi: 10.1200/JCO.18.01998.
    PubMed     Abstract available

  37. SHINDE A, Li R, Amini A, Glaser S, et al
    Can Immunotherapy Replace Radiotherapy in Melanoma Brain Metastases?
    J Clin Oncol. 2019 Feb 26:JCO1801982. doi: 10.1200/JCO.18.01982.

    November 2018
  38. KLUGER HM, Chiang V, Mahajan A, Zito CR, et al
    Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
    J Clin Oncol. 2018 Nov 8:JCO1800204. doi: 10.1200/JCO.18.00204.
    PubMed     Abstract available

    October 2018
  39. DAVAR D, Wang H, Chauvin JM, Pagliano O, et al
    Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
    J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632.
    PubMed     Abstract available

  40. HAUSCHILD A, Dummer R, Schadendorf D, Santinami M, et al
    Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219.
    PubMed     Abstract available

    March 2018
  41. CARVAJAL RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, et al
    Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
    J Clin Oncol. 2018 Mar 12:JCO2017741090. doi: 10.1200/JCO.2017.74.1090.
    PubMed     Abstract available

    February 2018
    Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?
    J Clin Oncol. 2018 Feb 1:JCO2017768275. doi: 10.1200/JCO.2017.76.8275.
    PubMed     Abstract available

    January 2018
  43. HORIGUCHI M, Uno H, Wei LJ
    Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment.
    J Clin Oncol. 2018 Jan 16:JCO2017760983. doi: 10.1200/JCO.2017.76.0983.

    December 2017
  44. ROBERT C, Ribas A, Hamid O, Daud A, et al
    Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
    J Clin Oncol. 2017 Dec 28:JCO2017756270. doi: 10.1200/JCO.2017.75.6270.
    PubMed     Abstract available

  45. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
    Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
    J Clin Oncol. 2017;35:4066-4077.
    PubMed     Abstract available

  46. WONG SL, Faries MB, Kennedy EB, Agarwala SS, et al
    Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.
    J Clin Oncol. 2017 Dec 12:JCO2017757724. doi: 10.1200/JCO.2017.75.7724.
    PubMed     Abstract available

    October 2017
  47. CARLINO MS, Sandhu S
    Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma.
    J Clin Oncol. 2017 Oct 19:JCO2017752055. doi: 10.1200/JCO.2017.75.2055.

  48. CALLAHAN MK, Kluger H, Postow MA, Segal NH, et al
    Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    J Clin Oncol. 2017 Oct 17:JCO2017722850. doi: 10.1200/JCO.2017.72.2850.
    PubMed     Abstract available

  49. LONG GV, Eroglu Z, Infante J, Patel S, et al
    Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
    J Clin Oncol. 2017 Oct 9:JCO2017741025. doi: 10.1200/JCO.2017.74.1025.
    PubMed     Abstract available

  50. CHESNEY J, Puzanov I, Collichio F, Singh P, et al
    Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
    J Clin Oncol. 2017 Oct 5:JCO2017737379. doi: 10.1200/JCO.2017.73.7379.
    PubMed     Abstract available

    September 2017
  51. SZNOL M, Ferrucci PF, Hogg D, Atkins MB, et al
    Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    J Clin Oncol. 2017 Sep 15:JCO2016721167. doi: 10.1200/JCO.2016.72.1167.
    PubMed     Abstract available

    August 2017
  52. SCHADENDORF D, Wolchok JD, Hodi FS, Chiarion-Sileni V, et al
    Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
    J Clin Oncol. 2017 Aug 25:JCO2017732289. doi: 10.1200/JCO.2017.73.2289.
    PubMed     Abstract available

    July 2017
  53. LARKIN J, Minor D, D'Angelo S, Neyns B, et al
    Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    J Clin Oncol. 2017 Jul 3:JCO2016718023. doi: 10.1200/JCO.2016.71.8023.
    PubMed     Abstract available

    June 2017
  54. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Abstract available

    April 2017
  55. HAYDU LE, Scolyer RA, Lo S, Quinn MJ, et al
    Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
    J Clin Oncol. 2017 Apr 4:JCO2016719393. doi: 10.1200/JCO.2016.71.9393.
    PubMed     Abstract available

    February 2017
  56. KOHN CG, Zeichner SB, Chen Q, Montero AJ, et al
    Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    J Clin Oncol. 2017 Feb 21:JCO2016696336. doi: 10.1200/JCO.2016.69.6336.
    PubMed     Abstract available

    January 2017
  57. AGARWALA SS, Lee SJ, Yip W, Rao UN, et al
    Phase III Randomized Study of 4 Weeks of High-Dose Interferon-alpha-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Rese
    J Clin Oncol. 2017 Jan 30:JCO2016702951. doi: 10.1200/JCO.2016.70.2951.
    PubMed     Abstract available

  58. D'ANGELO SP, Larkin J, Sosman JA, Lebbe C, et al
    Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
    J Clin Oncol. 2017;35:226-235.
    PubMed     Abstract available

  59. WATTS CG, Cust AE, Menzies SW, Mann GJ, et al
    Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
    J Clin Oncol. 2017;35:63-71.
    PubMed     Abstract available

    December 2016
    Pulmonary Infiltrates in a Patient With Advanced Melanoma.
    J Clin Oncol. 2016 Dec 28:JCO2016699793.
    PubMed     Abstract available

  61. DIENG M, Butow PN, Costa DS, Morton RL, et al
    Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2016;34:4405-4414.
    PubMed     Abstract available

  62. DAUD AI, Wolchok JD, Robert C, Hwu WJ, et al
    Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
    J Clin Oncol. 2016;34:4102-4109.
    PubMed     Abstract available

    November 2016
    Sunscreen Use in the Prevention of Melanoma: Common Sense Rules.
    J Clin Oncol. 2016;34:3956-3958.

  64. WEBER JS, Hodi FS, Wolchok JD, Topalian SL, et al
    Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
    J Clin Oncol. 2016 Nov 14:JCO2015661389.
    PubMed     Abstract available

    September 2016
  65. GHIASVAND R, Weiderpass E, Green AC, Lund E, et al
    Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study.
    J Clin Oncol. 2016 Sep 12. pii: JCO675934.
    PubMed     Abstract available

    January 2016
  66. BULLOCH KJ, Narayan D, Ariyan S, Gould Rothberg BE, et al
    Correlation of body mass index with female survival benefit among a single-institution cohort of cutaneous melanomas >1 mm thick following wide-local excision and sentinel lymph node biopsy.
    J Clin Oncol. 2016;34.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.